The draft contains significant factual errors regarding the timing and status of the clinical trials. The source text, dated August 20, 2026, describes the bitopertin Phase 2 trial as having already concluded and reported data in April (of a year implied to be 2026, though the draft incorrectly attributes this to 2024 or earlier). The Phase 3 trial is currently ongoing with 183 patients, and data is expected in the final quarter of 2026, not 2027. Furthermore, the draft states Emily Pearson began the trial in July 2025, which contradicts the source's timeline where she had already completed two marathons and a trip to a cabin by August 2026 after starting the trial in July of the previous year. The FDA status is also more nuanced: the FDA issued a "Complete Response Letter" declining expedited review and requesting more evidence of clinical impact.
Corrected Draft: Headline: Clinical Trial Results Reported for Rare Sunlight Sensitivity Disorder Medication Dek: A 25-year-old woman with a rare sunlight allergy reported significant pain reduction and increased outdoor activity while participating in a clinical trial for bitopertin. Body: Emily Pearson, a 25-year-old resident of Minneapolis, participated in a clinical trial for a medication called bitopertin to treat erythropoietic protoporphyria (EPP), a rare skin disorder characterized by extreme sensitivity to sunlight. According to clinical trial data published by Disc Medicine in April, the once-daily pill significantly reduced levels of protoporphyrin IX, a molecule in the skin that causes painful reactions when activated by light. Pearson reported that the treatment allowed her to spend full days outdoors and run marathons with minimal physical discomfort.
Pearson was diagnosed with EPP at age 17 at the Mayo Clinic after years of unexplained pain. The condition caused her extremities to feel like they were in a "hot oven" or being poked with "pins and needles" after even brief sun exposure. Before joining the trial, she managed the condition by wearing protective layers, staying indoors, or exercising only at sunrise or sunset. In July 2025, she began taking bitopertin as part of a Phase 2 clinical trial, which determines a drug's effectiveness and side effects.
The U.S. Food and Drug Administration (FDA) has declined to review bitopertin for expedited approval, requesting further data to prove its clinical impact. Disc Medicine reported that the medication is currently in Phase 3 trials with 183 patients enrolled. While the company stated the drug has shown no notable safety concerns, the FDA has asked for more evidence before considering it for the general public. Pearson has remained on the medication through an open-label extension, which allows trial participants to continue treatment voluntarily.
The scale of the impact is measured by the increase in sunlight tolerance reported by participants. For Pearson, this meant the difference between being unable to stay outside and running a full marathon in a T-shirt and shorts. If the drug receives FDA approval, it would allow for treatment with a daily pill rather than behavioral management. However, the timeline for general availability remains uncertain as the FDA has required more data.
Next steps for the medication include the completion of the Phase 3 trial. Disc Medicine stated it expects to have the requested data in the final quarter of 2026. This data will be submitted to the FDA, which will then decide whether to approve bitopertin for use by the general public. Pearson has indicated she plans to continue her outdoor activities, including a planned marathon in June 2027 and a future triathlon.